Snippet3 Sep 2024 07:43
Https://min.news/health/3c88b6879789b7a79dc841097c48e1d3.html
A well-known international magazine singled out "criticism": eating habits are bad all over the world, especially in China!
September 3, 2024 14:32
In addition, among the top 20 most populous countries in the world, the Chinese have a cardiovascular mortality rate of 57.99% due to poor diet, also ranking first!
Although the above two data are really "worrying", I also saw a piece of good news on the Internet recently. On August 29, the dietary supplement brand By-Health submitted a "help maintain normal platelet aggregation" "Function, beneficial to blood flow health." The declaration of this new function of health food has made it the first company in the industry to submit a new function declaration and product registration application. In the future, new nutritional products for cardiovascular health may also be released.
The protagonist of this application submitted by By-Health is Fruitflow®, a water-soluble tomato concentrate known as "natural aspirin". Compared with "aspirin", the most widely used famous drug in the world to prevent cardiovascular diseases, the biggest advantage of Qingluosin is that it is naturally extracted, not chemically synthesized, and has fewer side effects! After all, aspirin is also very famous for its side effects. Long-term use can cause damage to the gastric mucosa and also affect liver health!
Therefore, when the natural nutritional ingredient Qingluoxin was discovered, it attracted much attention and became one of the key research directions of the world's nutrition community and health industry. According to official information, By-Health has been focusing on the development of new cardiovascular health functions since 2015, spending tens of millions on research and development, and cooperating with many authoritative institutions such as the China Academy of Chinese Medical Sciences and Sun Yat-sen University. Working closely with universities, we established animal function test evaluation methods and population food trial evaluation methods that "help maintain normal platelet aggregation and contribute to healthy blood flow" and carried out systematic verification.
In terms of clinical research, BY-HEALTH enrolled 190 middle-aged and elderly people over the age of 50 to examine the effect of Qingluoxin on the degree of platelet aggregation after short-term intervention. Studies have shown that after 7 days of intervention, Qingluosin significantly reduced the platelet aggregation rate induced by ADP by 7.7%. Many of its research results have been published in authoritative international magazines such as "Journal of Functional Foods" and "Frontiers in Nutrition".
At present, there are not many companies in China that have conducted such in-depth research in the field of cardiovascular health. By-Health’s application for the new Luoxin tablets this time is based on the clinical verification and related mechanism research of
Sign In
Follow the stocks
